hut78 cutaneous t cell lymphoma cell line (ATCC)
ATCC is a verified supplier 
ATCC manufactures this product 
96
Structured Review
ATCC
hut78 cutaneous t cell lymphoma cell line
Hut78 Cutaneous T Cell Lymphoma Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 584 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hut78+cells/HuT+78/pmc13006415-480-20-27
Average 96 stars, based on 584 article reviews
Hut78 Cutaneous T Cell Lymphoma Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 584 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hut78+cells/HuT+78/pmc13006415-480-20-27
Average 96 stars, based on 584 article reviews
hut78 cutaneous t cell lymphoma cell line - by Bioz Stars,
2026-10
96/100 stars
Images
Related Articles
Olfactory:Article Title: Olfactory Receptors as Tumor Suppressors in Cutaneous T-Cell Lymphoma via p38γ Pathway Modulation Article Snippet: In line with these findings, our current study uncovered the role of p38γ in CTCL cells and elucidated its molecular dynamics that impinge on ORs within the framework of the TCR signaling pathway via two small molecules CSH71 and CSH18 that targeting p38γ’s lipid binding site. .. Previously, we showed that CSH71 (250 nM) strongly upregulates the Olfactory Transduction pathway in Article Title: Olfactory receptors as tumor suppressors in cutaneous T-cell lymphoma via p38γ pathway modulation Article Snippet: .. Previously, we showed that CSH71 (250 nM) strongly upregulates the olfactory transduction pathway in Transduction:Article Title: Olfactory Receptors as Tumor Suppressors in Cutaneous T-Cell Lymphoma via p38γ Pathway Modulation Article Snippet: In line with these findings, our current study uncovered the role of p38γ in CTCL cells and elucidated its molecular dynamics that impinge on ORs within the framework of the TCR signaling pathway via two small molecules CSH71 and CSH18 that targeting p38γ’s lipid binding site. .. Previously, we showed that CSH71 (250 nM) strongly upregulates the Olfactory Transduction pathway in Article Title: Olfactory receptors as tumor suppressors in cutaneous T-cell lymphoma via p38γ pathway modulation Article Snippet: .. Previously, we showed that CSH71 (250 nM) strongly upregulates the olfactory transduction pathway in Microarray:Article Title: Olfactory receptors as tumor suppressors in cutaneous T-cell lymphoma via p38γ pathway modulation Article Snippet: .. Previously, we showed that CSH71 (250 nM) strongly upregulates the olfactory transduction pathway in Cell Binding Assay:Article Title: BGB-A445, a novel non-ligand-blocking agonistic anti-OX40 antibody, exhibits superior immune activation and antitumor effects in preclinical models. Article Snippet: OX40 is a costimulatory receptor that is expressed primarily on activated CD4+, CD8+, and regulatory T cells.. The ligation of OX40 to its sole ligand OX40L potentiates T cell expansion, differentiation, and activation and also promotes dendritic cells to mature to enhance their cytokine production.. Therefore, the use of agonistic anti-OX40 antibodies for cancer immunotherapy has gained great interest. Transfection:Article Title: BGB-A445, a novel non-ligand-blocking agonistic anti-OX40 antibody, exhibits superior immune activation and antitumor effects in preclinical models. Article Snippet: OX40 is a costimulatory receptor that is expressed primarily on activated CD4+, CD8+, and regulatory T cells.. The ligation of OX40 to its sole ligand OX40L potentiates T cell expansion, differentiation, and activation and also promotes dendritic cells to mature to enhance their cytokine production.. Therefore, the use of agonistic anti-OX40 antibodies for cancer immunotherapy has gained great interest. Expressing:Article Title: BGB-A445, a novel non-ligand-blocking agonistic anti-OX40 antibody, exhibits superior immune activation and antitumor effects in preclinical models. Article Snippet: OX40 is a costimulatory receptor that is expressed primarily on activated CD4+, CD8+, and regulatory T cells.. The ligation of OX40 to its sole ligand OX40L potentiates T cell expansion, differentiation, and activation and also promotes dendritic cells to mature to enhance their cytokine production.. Therefore, the use of agonistic anti-OX40 antibodies for cancer immunotherapy has gained great interest. Plasmid Preparation:Article Title: BGB-A445, a novel non-ligand-blocking agonistic anti-OX40 antibody, exhibits superior immune activation and antitumor effects in preclinical models. Article Snippet: OX40 is a costimulatory receptor that is expressed primarily on activated CD4+, CD8+, and regulatory T cells.. The ligation of OX40 to its sole ligand OX40L potentiates T cell expansion, differentiation, and activation and also promotes dendritic cells to mature to enhance their cytokine production.. Therefore, the use of agonistic anti-OX40 antibodies for cancer immunotherapy has gained great interest. Selection:Article Title: BGB-A445, a novel non-ligand-blocking agonistic anti-OX40 antibody, exhibits superior immune activation and antitumor effects in preclinical models. Article Snippet: OX40 is a costimulatory receptor that is expressed primarily on activated CD4+, CD8+, and regulatory T cells.. The ligation of OX40 to its sole ligand OX40L potentiates T cell expansion, differentiation, and activation and also promotes dendritic cells to mature to enhance their cytokine production.. Therefore, the use of agonistic anti-OX40 antibodies for cancer immunotherapy has gained great interest. Cell Culture:Article Title: Reprogramming of PD-1+ M2-like tumor-associated macrophages with anti-PD-L1 and lenalidomide in cutaneous T cell lymphoma. Article Snippet: .. Cell culture MyLa and Article Title: Reprogramming of PD-1 + M2-like tumor-associated macrophages with anti–PD-L1 and lenalidomide in cutaneous T cell lymphoma Article Snippet: .. MyLa and Generated:Article Title: BGB-A445, a novel non-ligand-blocking agonistic anti-OX40 antibody, exhibits superior immune activation and antitumor effects in preclinical models. Article Snippet: OX40 is a costimulatory receptor that is expressed primarily on activated CD4+, CD8+, and regulatory T cells.. The ligation of OX40 to its sole ligand OX40L potentiates T cell expansion, differentiation, and activation and also promotes dendritic cells to mature to enhance their cytokine production.. Therefore, the use of agonistic anti-OX40 antibodies for cancer immunotherapy has gained great interest. Stable Transfection:Article Title: BGB-A445, a novel non-ligand-blocking agonistic anti-OX40 antibody, exhibits superior immune activation and antitumor effects in preclinical models. Article Snippet: OX40 is a costimulatory receptor that is expressed primarily on activated CD4+, CD8+, and regulatory T cells.. The ligation of OX40 to its sole ligand OX40L potentiates T cell expansion, differentiation, and activation and also promotes dendritic cells to mature to enhance their cytokine production.. Therefore, the use of agonistic anti-OX40 antibodies for cancer immunotherapy has gained great interest. |
